2017
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors
Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O’Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors. Advances In Anatomic Pathology 2017, 24: 311-335. PMID: 28777143, PMCID: PMC5638696, DOI: 10.1097/pap.0000000000000161.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBiopsyBrain NeoplasmsCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellEndometrial NeoplasmsFemaleGastrointestinal NeoplasmsHead and Neck NeoplasmsHumansImmunohistochemistryLung NeoplasmsLymphocytes, Tumor-InfiltratingMelanomaMesotheliomaOvarian NeoplasmsPathologyPhenotypePredictive Value of TestsSkin NeoplasmsSquamous Cell Carcinoma of Head and NeckUrogenital NeoplasmsConceptsTumor-infiltrating lymphocytesDifferent tumor typesSolid tumorsTumor typesTIL assessmentImmune responsePrimary brain tumorsCommon solid tumorsInvasive breast carcinomaRoutine clinical biomarkersWorking Group guidelinesPrognostic implicationsBreast carcinomaGroup guidelinesGynecologic systemGastrointestinal tractSimple biomarkerBrain tumorsGenitourinary systemPredictive valueClinical biomarkersStandardized methodologyTumorsAvailable evidenceImmunotherapy
2016
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelakanou V, Rehman J, Velcheti V, Herbst R, LoRusso P, Rimm DL. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer. JAMA Oncology 2016, 2: 1-9. PMID: 26562159, PMCID: PMC4941982, DOI: 10.1001/jamaoncol.2015.3638.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, MonoclonalAntibody SpecificityB7-H1 AntigenBiomarkers, TumorCarcinoma, Non-Small-Cell LungFemaleFluorescent Antibody TechniqueHumansImmunohistochemistryLung NeoplasmsMaleObserver VariationPredictive Value of TestsReproducibility of ResultsRetrospective StudiesTissue Array AnalysisConceptsTumor-infiltrating lymphocytesPD-L1 expressionPD-L1 antibodiesPD-L1 protein expressionCell lung cancerPD-L1Whole tissue sectionsQuantitative immunofluorescenceLung cancerChromogenic immunohistochemistryPoor concordanceDifferent PD-L1 antibodiesHigh tumor-infiltrating lymphocytesTumor PD-L1 expressionPD-L1 protein levelsCell lung cancer biopsiesMonoclonal antibodiesCurrent consensus guidelinesProtein expressionDurable clinical responsesMain outcome measuresEarly phase trialsLung cancer biopsiesRabbit monoclonal antibodyCorresponding tissue microarrays
2015
Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer
Carvajal-Hausdorf DE, Schalper KA, Pusztai L, Psyrri A, Kalogeras KT, Kotoula V, Fountzilas G, Rimm DL. Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer. Journal Of The National Cancer Institute 2015, 107: djv136. PMID: 25991002, PMCID: PMC4554192, DOI: 10.1093/jnci/djv136.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantClinical Trials as TopicDisease-Free SurvivalExtracellular SpaceFemaleFluorescent Antibody TechniqueGene Expression Regulation, NeoplasticHumansIntracellular SpaceKaplan-Meier EstimateMiddle AgedPredictive Value of TestsPrognosisReceptor, ErbB-2Sensitivity and SpecificityTissue Array AnalysisTrastuzumabTreatment OutcomeConceptsHuman epidermal growth factor receptor 2ECD expressionICD statusLonger DFSQuantitative immunofluorescenceTrastuzumab therapyPrognostic valueBreast cancerTissue microarrayEpidermal growth factor receptor 2Adjuvant trastuzumab therapyDisease-free survival analysisTrastuzumab-treated patientsGrowth factor receptor 2High positive predictive valueHER2-positive tumorsKaplan-Meier estimatesFactor receptor 2ERBB2 gene amplificationHER2 protein expressionPositive predictive valueExtracellular domainAdjuvant chemotherapyHER2-ICDBetter DFSObjective Measurement and Clinical Significance of TILs in Non–Small Cell Lung Cancer
Schalper KA, Brown J, Carvajal-Hausdorf D, McLaughlin J, Velcheti V, Syrigos KN, Herbst RS, Rimm DL. Objective Measurement and Clinical Significance of TILs in Non–Small Cell Lung Cancer. Journal Of The National Cancer Institute 2015, 107: dju435. PMID: 25650315, PMCID: PMC4565530, DOI: 10.1093/jnci/dju435.Peer-Reviewed Original ResearchMeSH KeywordsAntigens, CD20Carcinoma, Non-Small-Cell LungCD3 ComplexCD8 AntigensConfounding Factors, EpidemiologicFluorescent DyesHumansIndolesKaplan-Meier EstimateLung NeoplasmsLymphocytes, Tumor-InfiltratingMicroscopy, FluorescencePredictive Value of TestsRetrospective StudiesT-Lymphocytes, CytotoxicConceptsTumor-infiltrating lymphocytesLevels of CD3TIL subtypesMultivariable analysisTumor sizeLonger survivalAssociation of TILsLevel of TILsNon-small cell lung cancerNon-small cell lung cancer samplesLocal immune effectsClinico-pathologic characteristicsImmune checkpoint inhibitorsCell lung cancerCell lung cancer samplesLung cancer samplesDifferent tumor compartmentsObjective measurementsElevated CD3High CD20TIL markersTIL subpopulationsCheckpoint inhibitorsSmoking historyHistology type
2013
Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker
Sgroi DC, Carney E, Zarrella E, Steffel L, Binns SN, Finkelstein DM, Szymonifka J, Bhan AK, Shepherd LE, Zhang Y, Schnabel CA, Erlander MG, Ingle JN, Porter P, Muss HB, Pritchard KI, Tu D, Rimm DL, Goss PE. Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker. Journal Of The National Cancer Institute 2013, 105: 1036-1042. PMID: 23812955, PMCID: PMC3888138, DOI: 10.1093/jnci/djt146.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsAromatase InhibitorsBiomarkers, TumorBreast NeoplasmsCase-Control StudiesChemotherapy, AdjuvantDisease-Free SurvivalFemaleHomeodomain ProteinsHumansIncidenceLetrozoleLogistic ModelsMiddle AgedMultivariate AnalysisNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingNitrilesPredictive Value of TestsPrognosisProspective StudiesReceptor, ErbB-2Receptors, EstrogenReceptors, InterleukinReceptors, Interleukin-17Receptors, ProgesteroneRetrospective StudiesReverse Transcriptase Polymerase Chain ReactionTriazolesConceptsExtended letrozole therapyStandard clinicopathological factorsLate disease recurrenceLate recurrenceLetrozole therapyEndocrine therapyDisease recurrenceClinicopathological factorsLymph node-negative breast cancer patientsNode-negative breast cancer patientsExtended adjuvant endocrine therapyMultivariable conditional logistic regressionExtended adjuvant letrozolePlacebo-treated patientsAdjuvant endocrine therapyER-positive patientsBreast cancer patientsPositive breast cancerConditional logistic regressionReverse transcription-polymerase chain reactionCase-control designAdjuvant letrozoleLetrozole treatmentAbsolute riskCancer patients
2012
Quantitative In Situ Measurement of Estrogen Receptor mRNA Predicts Response to Tamoxifen
Bordeaux JM, Cheng H, Welsh AW, Haffty BG, Lannin DR, Wu X, Su N, Ma XJ, Luo Y, Rimm DL. Quantitative In Situ Measurement of Estrogen Receptor mRNA Predicts Response to Tamoxifen. PLOS ONE 2012, 7: e36559. PMID: 22606272, PMCID: PMC3350519, DOI: 10.1371/journal.pone.0036559.Peer-Reviewed Original ResearchStathmin expression and its relationship to microtubule‐associated protein tau and outcome in breast cancer
Baquero MT, Hanna JA, Neumeister V, Cheng H, Molinaro AM, Harris LN, Rimm DL. Stathmin expression and its relationship to microtubule‐associated protein tau and outcome in breast cancer. Cancer 2012, 118: 4660-4669. PMID: 22359235, PMCID: PMC3391341, DOI: 10.1002/cncr.27453.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnalysis of VarianceBiomarkers, TumorBlotting, WesternBreastBreast NeoplasmsCell Line, TumorCohort StudiesFemaleFluorescent Antibody TechniqueGene Expression Regulation, NeoplasticHumansImmunohistochemistryKaplan-Meier EstimateLymphatic MetastasisMiddle AgedNeoplasm GradingNeoplasm StagingOdds RatioPredictive Value of TestsPrognosisProportional Hazards ModelsRisk AssessmentRisk FactorsRNA, Small InterferingStathminTau ProteinsTissue Array AnalysisTreatment OutcomeConceptsHigh stathmin expressionDisease-free survivalMAP-tauOverall survivalStathmin expressionBreast cancerHuman epidermal growth factor receptor 2 (HER2) expressionEpidermal growth factor receptor 2 expressionMultivariate analysisCox proportional hazards modelWorse overall survivalReceptor 2 expressionTissue microarray formatMicrotubule-associated protein tauProportional hazards modelBreast cancer cohortIndependent predictorsMenopausal statusNodal statusBetter prognosisPrognostic valueTumor sizePathological characteristicsProgesterone receptorNuclear gradeAssociation between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer
Andre F, Conforti R, Moeder CB, Mauguen A, Arnedos M, Berrada N, Delaloge S, Tomasic G, Spielmann M, Esteva FJ, Rimm DL, Michiels S. Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer. Annals Of Oncology 2012, 23: 2059-2064. PMID: 22241898, DOI: 10.1093/annonc/mdr569.Peer-Reviewed Original ResearchConceptsAnthracycline-based chemotherapyEarly breast cancerNuclear/cytoplasmic (N/C) ratioCytoplasmic ratioAdjuvant chemotherapyHazard ratioBreast cancerP27 expressionNuclear expressionAdjusted hazard ratioNuclear p27 expressionAdjuvant polychemotherapyUntreated armPrognostic parametersTissue microarrayChemotherapyPatientsPredictive valueImmunofluorescence assaysQuantitative immunofluorescence assaysEfficacyP27CancerExpressionPolychemotherapy
2011
Comparative Prognostic Value of Epidermal Growth Factor Quantitative Protein Expression Compared with FISH for Head and Neck Squamous Cell Carcinoma
Pectasides E, Rampias T, Kountourakis P, Sasaki C, Kowalski D, Fountzilas G, Zaramboukas T, Rimm D, Burtness B, Psyrri A. Comparative Prognostic Value of Epidermal Growth Factor Quantitative Protein Expression Compared with FISH for Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research 2011, 17: 2947-2954. PMID: 21355076, DOI: 10.1158/1078-0432.ccr-10-2040.Peer-Reviewed Original ResearchCarcinomaCarcinoma, Squamous CellEpidermal Growth FactorFemaleGene DosageGene Expression Regulation, NeoplasticHead and Neck NeoplasmsHumansIn Situ Hybridization, FluorescenceMaleNeoplasms, Squamous CellPredictive Value of TestsPrognosisProteinsSquamous Cell Carcinoma of Head and NeckSurvival AnalysisTissue Array AnalysisEvaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts
Baquero MT, Lostritto K, Gustavson MD, Bassi KA, Appia F, Camp RL, Molinaro AM, Harris LN, Rimm DL. Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts. Breast Cancer Research 2011, 13: r85. PMID: 21888627, PMCID: PMC3262195, DOI: 10.1186/bcr2937.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsCohort StudiesCyclophosphamideCytoplasmDocetaxelDoxorubicinEpithelial CellsFemaleFluorouracilHumansKaplan-Meier EstimateMiddle AgedPredictive Value of TestsPrognosisRandomized Controlled Trials as TopicRetrospective StudiesSurvival RateTau ProteinsTaxoidsConceptsOverall survivalBreast cancer cohortTreatment armsPredictive markerCancer cohortPredictive valueResponse rateConventional whole tissue sectionsMAP-tauImproved overall survivalHigh expressionMicrotubule associated protein tauTaxane-based chemotherapyKaplan-Meier analysisLonger median timeUseful predictive markerCox univariate analysisIndependent breast cancer cohortsWhole tissue sectionsFAC chemotherapyLonger TTPMedian timeMeier analysisPrognostic valueClinicopathologic variables
2010
Biomarkers: The Useful and the Not So Useful—An Assessment of Molecular Prognostic Markers for Cutaneous Melanoma
Rothberg BE, Rimm DL. Biomarkers: The Useful and the Not So Useful—An Assessment of Molecular Prognostic Markers for Cutaneous Melanoma. Journal Of Investigative Dermatology 2010, 130: 1971-1987. PMID: 20555347, PMCID: PMC3180927, DOI: 10.1038/jid.2010.149.Peer-Reviewed Original ResearchBiomarkers, TumorHumansMelanomaNeoplasm InvasivenessPredictive Value of TestsPrognosisSkin NeoplasmsHigh expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology
Anagnostou VK, Lowery FJ, Zolota V, Tzelepi V, Gopinath A, Liceaga C, Panagopoulos N, Frangia K, Tanoue L, Boffa D, Gettinger S, Detterbeck F, Homer RJ, Dougenis D, Rimm DL, Syrigos KN. High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology. BMC Cancer 2010, 10: 186. PMID: 20459695, PMCID: PMC2875218, DOI: 10.1186/1471-2407-10-186.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedBiomarkers, TumorCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCell DifferentiationCohort StudiesConnecticutFemaleGreeceHumansKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedNeoplasm StagingPredictive Value of TestsProportional Hazards ModelsProto-Oncogene Proteins c-bcl-2Reproducibility of ResultsRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUp-RegulationConceptsNon-small cell lung cancer patientsCell lung cancer patientsNon-squamous tumorsLung cancer patientsBcl-2 expressionNSCLC patientsCancer patientsBcl-2Favorable outcomeIndependent cohortSmall cell lung cancer patientsIndependent lower riskNon-squamous histologySubgroup of patientsHigh expressersSquamous cell carcinomaHigh Bcl-2 expressionBcl-2 protein levelsSquamous histologyMedian survivalPrognostic factorsValidation cohortCell carcinomaPathological characteristicsPrognostic stratification
2009
Tissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-analysis
Rothberg BE, Bracken MB, Rimm DL. Tissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-analysis. Journal Of The National Cancer Institute 2009, 101: 452-474. PMID: 19318635, PMCID: PMC2720709, DOI: 10.1093/jnci/djp038.Peer-Reviewed Original ResearchConceptsCohort studyCutaneous melanomaMelanoma cell adhesion moleculeSystematic reviewEarly-stage cutaneous melanomaPotential prognostic valueMatrix metalloproteinase-2Cell nuclear antigenREMARK criteriaAdjuvant therapyMultivariable analysisREMARK guidelinesRisk stratificationPrognostic valueSurvival outcomesIncomplete adherenceMelanoma outcomesClinical managementImmunohistochemical expressionCell adhesion moleculeInclusion criteriaKi-67Tissue biomarkersClinical practiceMetalloproteinase-2
2008
Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer.
Giltnane JM, Molinaro A, Cheng H, Robinson A, Turbin D, Gelmon K, Huntsman D, Rimm DL. Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer. Archives Of Pathology & Laboratory Medicine 2008, 132: 1635-47. PMID: 18834223, DOI: 10.5858/2008-132-1635-coqiwc.Peer-Reviewed Original ResearchAnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBreast NeoplasmsCell LineCricetinaeFemaleHumansImmunohistochemistryIn Situ Hybridization, FluorescenceLogistic ModelsMiddle AgedPredictive Value of TestsReceptor, ErbB-2Retrospective StudiesSensitivity and SpecificityTissue Array AnalysisTrastuzumabTreatment OutcomeExpression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer
Nadler Y, Camp RL, Giltnane JM, Moeder C, Rimm DL, Kluger HM, Kluger Y. Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer. Breast Cancer Research 2008, 10: r35. PMID: 18430249, PMCID: PMC2397537, DOI: 10.1186/bcr1998.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsBiomarkers, TumorBreast NeoplasmsDNA-Binding ProteinsDrug Resistance, NeoplasmFemaleFluorescent Antibody TechniqueFollow-Up StudiesGene Expression Regulation, NeoplasticHumansImmunohistochemistryKaplan-Meier EstimateLymphatic MetastasisMiddle AgedPredictive Value of TestsPrognosisProportional Hazards ModelsProtein Array AnalysisProto-Oncogene Proteins c-bcl-2Receptors, EstrogenReceptors, ProgesteroneTranscription FactorsTreatment OutcomeConceptsNode-positive subsetHER2/neuProgesterone receptorBreast cancerEstrogen receptorBcl-2 expressionBAG-1 expressionImproved survivalBcl-2Anti-apoptotic mediator Bcl-2Breast tumorsSteroid receptor positivitySubset of patientsBAG-1Antihormonal therapyFavorable prognosisReceptor positivityMultivariable analysisPathological variablesEntire cohortPrognostic valuePrognostic markerImproved outcomesLarge cohortClinical development
2007
Fine‐needle aspiration of follicular adenoma versus parathyroid adenoma
Mansoor I, Zalles C, Zahid F, Gossage K, Levenson RM, Rimm DL. Fine‐needle aspiration of follicular adenoma versus parathyroid adenoma. Cancer 2007, 114: 22-26. PMID: 18085636, DOI: 10.1002/cncr.23252.Peer-Reviewed Original ResearchMeSH KeywordsAdenomaDiagnosis, DifferentialDiagnostic ImagingHumansParathyroid NeoplasmsPredictive Value of TestsSensitivity and SpecificitySpectrum AnalysisThyroid NeoplasmsConceptsArtificial intelligence systemsSpatial-spectral featuresSpectral image informationMultispectral image analysisIntelligence systemsImage informationAlgorithmic solutionTraining setImage stacksImaging solutionImage analysisTest casesHuman eyeImagesClassifierSoftwareToolPlatformSolutionTechnologyInformationSetQuantitative Measurement of Epidermal Growth Factor Receptor Is a Negative Predictive Factor for Tamoxifen Response in Hormone Receptor–Positive Premenopausal Breast Cancer
Giltnane JM, Rydén L, Cregger M, Bendahl PO, Jirström K, Rimm DL. Quantitative Measurement of Epidermal Growth Factor Receptor Is a Negative Predictive Factor for Tamoxifen Response in Hormone Receptor–Positive Premenopausal Breast Cancer. Journal Of Clinical Oncology 2007, 25: 3007-3014. PMID: 17634479, DOI: 10.1200/jco.2006.08.9938.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkersBiopsy, NeedleBreast NeoplasmsDrug Resistance, NeoplasmErbB ReceptorsEstrogen AntagonistsFemaleHumansImmunohistochemistryMiddle AgedMultivariate AnalysisPredictive Value of TestsPremenopauseProbabilityProportional Hazards ModelsReceptors, EstrogenRisk AssessmentSensitivity and SpecificitySurvival AnalysisTamoxifenConceptsEpidermal growth factor receptorER-positive patientsEGFR expressionBreast cancerEstrogen receptorTamoxifen-treated patientsEarly breast cancerRecurrence-free survivalRandomized clinical trialsLow EGFR expressionSignificant beneficial effectAdjuvant tamoxifenGrowth factor receptorEndocrine therapyTamoxifen responseTamoxifen treatmentClinical trialsSitu protein expressionUntreated groupTissue microarrayPatientsBeneficial effectsProtein expressionFactor receptorTreatment effectsPhosphorylation of Akt (Ser473) Predicts Poor Clinical Outcome in Oropharyngeal Squamous Cell Cancer
Yu Z, Weinberger PM, Sasaki C, Egleston BL, Speier WF, Haffty B, Kowalski D, Camp R, Rimm D, Vairaktaris E, Burtness B, Psyrri A. Phosphorylation of Akt (Ser473) Predicts Poor Clinical Outcome in Oropharyngeal Squamous Cell Cancer. Cancer Epidemiology Biomarkers & Prevention 2007, 16: 553-558. PMID: 17372251, DOI: 10.1158/1055-9965.epi-06-0121.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorCarcinoma, Squamous CellChi-Square DistributionFemaleHumansImmunoenzyme TechniquesMaleMiddle AgedNeoplasm Recurrence, LocalOropharyngeal NeoplasmsPhosphorylationPredictive Value of TestsPrognosisProportional Hazards ModelsProtein Array AnalysisProto-Oncogene Proteins c-aktPTEN PhosphohydrolaseSurvival AnalysisConceptsNuclear p-AktAkt activationP-AktOropharyngeal squamous cell cancerSquamous cell carcinoma progressionPhosphorylated AktCohort of patientsLocal recurrence rateOverall survival rateSquamous cell cancerPoor clinical outcomeAdverse patient outcomesP-AKT levelsPromising molecular targetP-AKT expressionProtein expression levelsPhosphorylation of AktDisease recurrenceLocal recurrenceCell cancerClinical outcomesAdjusted analysisPrognostic significanceRecurrence ratePatient outcomes
2006
Classification of Breast Cancer Using Genetic Algorithms and Tissue Microarrays
Dolled-Filhart M, Rydén L, Cregger M, Jirström K, Harigopal M, Camp RL, Rimm DL. Classification of Breast Cancer Using Genetic Algorithms and Tissue Microarrays. Clinical Cancer Research 2006, 12: 6459-6468. PMID: 17085660, DOI: 10.1158/1078-0432.ccr-06-1383.Peer-Reviewed Original ResearchConceptsBreast cancerPatient outcomesTissue microarraySubset of patientsBreast cancer patientsTissue microarray platformInternal validation setRoutine pathology laboratoriesCancer patientsEstrogen receptorTissue biomarkersIndependent cohortTumor subtypesPredictive valueAcid-base analysisPathology laboratoryRNA expression studiesCancerTissue sectionsPatientsCohortOutcomesFurther validationObjective quantitative analysisBiomarker discovery
2005
Automated Quantitative Analysis (AQUA) of In Situ Protein Expression, Antibody Concentration, and Prognosis
McCabe A, Dolled-Filhart M, Camp RL, Rimm DL. Automated Quantitative Analysis (AQUA) of In Situ Protein Expression, Antibody Concentration, and Prognosis. Journal Of The National Cancer Institute 2005, 97: 1808-1815. PMID: 16368942, DOI: 10.1093/jnci/dji427.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, NeoplasmBiomarkers, TumorCell Line, TumorConfidence IntervalsEnzyme-Linked Immunosorbent AssayFemaleFluorescent Antibody TechniqueGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmunohistochemistryMaleMiddle AgedNeoplasmsOdds RatioPredictive Value of TestsPrognosisProtein Array AnalysisReceptor, ErbB-2Receptors, EstrogenSurvival AnalysisTreatment OutcomeTumor Suppressor Protein p53ConceptsDisease-specific mortalityHigh HER2 expressionHER2 expressionAntibody concentrationsHigh expressionPoor survivalRelative riskTissue microarrayCumulative disease-specific survivalBiomarker expressionLong-term survival dataLow expressionHER2 antibodyX-tile programDisease-specific survivalLow HER2 expressionKaplan-Meier methodBreast cancer patientsExpression of HER2Higher antibody concentrationsLow antibody concentrationsConcentration of antibodyCancer patientsPatient outcomesSitu protein expression